← All trials
NCT05157542
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 10, 2021
- Primary completion
- Jun 10, 2023
- Completion date
- Jun 10, 2023
- First posted
- Dec 15, 2021
- Last posted
- Dec 15, 2021
- Enrollment
- 9
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Sichuan Cancer Hospital and Research InstituteLead sponsor
- University of Electronic Science and Technology of ChinaSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.